Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FluorApoTrace for Apoptosis Imaging in Lymphoma
NCT05048732Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-FluorApoTrace in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Whole body effective dose at Day 1, Radiation doses to critical organs at Day 1 and 2 more. Started Dec 2021; status: terminated.
02
Drugs
18F-FluorApoTrace
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05048732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048732.